Quoin Pharmaceuticals, Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| QNRX | VRCA | FBIO | HIND | CTXR | PVLA | |
|---|---|---|---|---|---|---|
| Market cap | 19.31M | 59.35M | 65.70M | 12.18M | 15.13M | 2.34B |
| P/E (TTM) | — | — | 0.7 | 1.0 | — | — |
| Forward P/E | -1.3 | -2.8 | -1.1 | — | -0.4 | -20.5 |
| Price/book | 2.1 | 13.8 | 0.4 | 2.0 | 0.2 | 10.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −53.09% | −3.49% | −21.83% | −70.33% | −55.56% | +106.38% |
| Today | +2.29% | +5.02% | +1.55% | −1.93% | −3.87% | +6.11% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All QNRX news ›Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Sees Significant Decrease in Short Interest
Posted by Danessa Lincoln on Oct 30th, 2026 View Our Latest Research Report on QNRX Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($1.90) EPS…
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe after receipt of…
Quoin Pharmaceuticals, Ltd. Sponsored ADR (QNRX) – What Are Investment Firms Thinking About This Stock?
Posted by Tristan Rich on Oct 26th, 2026 View Our Latest Research Report on QNRX Shares of QNRX stock opened at $4.07 on Monday. The stock’s fifty day moving average price is $5.55 and its two-hundred day moving average price is $5.22. The…
Quoin Pharmaceuticals publishes peer-reviewed paper on QRX003 for rare skin disease
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the publication of a peer-reviewed manuscript on its investigational drug QRX003 for Netherton Syndrome in the journal Dermatology and Therapy. The paper was published online on Oct. 13,…
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
Northrop Grumman Releases Third Quarter 2026 Financial Results The pediatric case adds 21 months of treatment observations, while Phase 2/3 topline data are expected in Q2 2027. Separately, four of the first six participants completing 12…
Quoin Pharmaceuticals (NASDAQ:QNRX) Upgraded at Wall Street Zen
Posted by Kim Johansen on Oct 20th, 2026 Wall Street Zen upgraded shares of Quoin Pharmaceuticals (NASDAQ:QNRX – Free Report) to a sell rating in a research note released on Saturday,Wall Street Zen reports. View Our Latest Stock Report on…
Quoin Pharmaceuticals’ QRX003 Receives EMA Orphan Drug Designation for Peeling Skin Syndrome, on Track for First Clinical Trial
Quoin Pharmaceuticals announces clinical trial plans and orphan drug designation for QRX003, targeting Peeling Skin Syndrome. The Orphan Drug designation provides QRX003 with 10 years of market exclusivity in Europe for Peeling Skin…
Quoin Pharmaceuticals Announces Peer-Reviewed Publication Introducing QRX003 and Reporting Positive Pediatric Compassionate-Use Results in Netherton Syndrome
Quoin Pharmaceuticals publishes a paper on QRX003 for Netherton Syndrome, detailing positive pediatric case report outcomes. QRX003 is an investigational topical serine protease inhibitor lotion aimed at treating Netherton Syndrome and…
Quoin Pharmaceuticals (NASDAQ:QNRX) Now Covered by Canaccord Genuity Group
Posted by Mitch Edgeman on Oct 20th, 2026 Canaccord Genuity Group started coverage on shares of Quoin Pharmaceuticals (NASDAQ:QNRX – Free Report) in a research report sent to investors on Monday, MarketBeat.com reports. The firm issued a…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com5
- stocktitan.net2
- defenseworld.net1
- globenewswire.com1
- quiverquant.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.